Research Beam added a report on “Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth” Enquiry about report: http://www.researchbeam.com/global-immunology-to-2022-large-pipeline-and-competitive-to-drive-long-term-growth-market/enquire-about-report
Big Market Research, Vasomotor Symptoms of Menopause Market, Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘Vasomotor Symptoms of Menopause - Pipeline Review, H2 2014’, provides an overview of the Vasomotor Symptoms of Menopause’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vasomotor Symptoms of Menopause, complete with comparative analysis at various stages, therapeutics assessment by drug target.
GBI Research, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth” Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas. Enquiry @ http://www.researchbeam.com/melanoma-therapeutics-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-growth-market/enquire-about-report
Big Market Research adds a report “Pancreatic Cancer Therapeutics in Major Developed Markets- Size, Share, Trends, Forecast, Growth, Opportunities, Outlook " Get Complete Report @ http://www.bigmarketresearch.com/pancreatic-cancer-therapeutics-in-major-developed-to-2021-strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-landscape-market The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period. Enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/373733
Download Sample Brochure @ http://tinyurl.com/hwlwn6x Marketintelreports, ‘Melanoma - Pipeline Review, H2 2015’, provides an overview of the Melanoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects.
GBI Research, a leading business intelligence provider, has released its latest research report, Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. Enquiry @ http://www.researchbeam.com/asthma-therapeutics-in-major-developed-to-2020-personalized-treatment-for-severe-asthma-to-drive-growth-despite-patent-expirations-market/enquire-about-report
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. Enquiry @ http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-major-developed-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report
Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Enquiry @ http://www.researchbeam.com/hepatitis-b-therapeutics-in-major-developed-to-2021-increasing-number-of-migrants-from-high-prevalence-regions-to-drive-growth-market/enquire-about-report
Research Beam added a report on “Vasomotor Symptoms of Menopause (Hot Flashes) Global Clinical Trials Review, H2, 2015” Enquiry about report: http://www.researchbeam.com/vasomotor-symptoms-of-menopause-hot-flashes-global-clinical-trials-review-h2-2015-market/enquire-about-report
Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019. The scope of the report give a brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis- In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. For More Details:http://www.researchonglobalmarkets.com/type-2-diabetes-therapeutics-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019.html
Asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.
Big Market Research, Abdominal Aortic Aneurysms Market, Size, Share, Global Industry, Growth, Trends, Forecast, Analysis, Pipeline Review 2014. Global Markets Direct’s, ‘Abdominal Aortic Aneurysms - Pipeline Review, H2 2014’, provides an overview of the Abdominal Aortic Aneurysms’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Abdominal Aortic Aneurysms, complete with comparative analysis at various stages, therapeutics assessment by drug target
Download Sample Brochure of Report @ http://tinyurl.com/ja94rae A detailed qualitative analysis of the factors responsible for driving and restraining growth of the MRI Systems Market and future opportunities are provided in the report.
Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Amyloidosis Therapeutics market.
The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. Detailed report at: http://www.reportsandintelligence.com/pancreatic-adenocarcinoma-therapeutics-in-major-developed-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant-market
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market.
“Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market.
The report entitled “US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)”, provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc. Complete report available at http://www.marketreportsonline.com/535595.html.
GBI Research, the leading business intelligence provider, has released its latest research: Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis. Enquiry @ http://www.researchbeam.com/colorectal-cancer-therapeutics-in-major-developed-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics-market/enquire-about-report
The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research team of industry experts. Enquiry @ http://www.researchbeam.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market/enquire-about-report
Big Market Research has announced a new report “COPD Therapeutics in Major Developed Markets - Size, Share, Trends, Forecast, Growth, Opportunities 2021” Get Complete Report @ http://www.bigmarketresearch.com/copd-therapeutics-in-major-developed-to-2021-emergence-of-addition-in-class-and-first-in-class-products-offsets-sales-erosion-of-leading-brands-market There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease. Enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/373731
‘Sicca Syndrome (Sjogren) - Pipeline Review, H1 2016’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. Read More At: http://www.researchbeam.com/sicca-syndrome-sjogren-pipeline-review-h1-2016-market
GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake”. There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬-resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011. Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. View full report with TOC: http://www.reportsandintelligence.com/therapeutic-cancer-vaccines-to-2019-pipeline-indicates-safer-treatments-and-extended-patient-survival-though-high-prices-may-limit-uptake-market
‘Hyperglycemia - Pipeline Review, H1 2016’, provides an overview of the Hyperglycemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. Read More At: http://www.researchbeam.com/hyperglycemia-pipeline-review-h1-2016-market
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. Enquiry @ http://www.researchbeam.com/anti-hypertensive-therapeutics-in-asia-pacific-to-2021-increasing-prevalence-of-hypertension-drives-growth-despite-weak-pipeline-market/enquire-about-report
Diabetic foot ulcers (DFUs) are a common complication of diabetes. With the increasing prevalence of diabetes across all markets the number of patients suffering from DFUs is also expected to rise. The global DFU therapeutics market is set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years. The first two topical antibacterial are also expected to be launched in the US and the five major EU markets. With the advent of these new product launches, the size of the DFU market is expected to grow substantially by 2017. For more details: http://www.researchonglobalmarkets.com/opportunityanalyzer-diabetic-foot-ulcers-opportunity-analysis-and-forecast-to-2017.html
Download Sample Brochure @ http://tinyurl.com/j5wwlly Marketintelreports, ‘Osteoarthritis - Pipeline Review, H1 2015’, provides an overview of the Osteoarthritis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects.
Download Sample Brochure @ http://tinyurl.com/j2s4dna Marketintelreports, ‘HIV / AIDS - Pipeline Review, H2 2015’, provides an overview of the HIV / AIDS’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for HIV / AIDS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDS and special features on late-stage and discontinued projects.
Download Sample Brochure@ http://tinyurl.com/h6z57zs Marketintelreports, ‘Huntington's Disease - Pipeline Review, H2 2015’, provides an overview of the Huntington's disease’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Huntington's disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's disease and special features on late-stage and discontinued projects.
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%. Enquiry @ http://www.researchbeam.com/multiple-myeloma-therapeutics-in-major-developed-to-2021-growth-driven-by-rising-prevalence-continued-success-of-revlimid-and-emerging-supplementary-treatments-market/enquire-about-report
Download Sample Brochure @ http://tinyurl.com/hrk5w6o Marketintelreports, ‘Psoriasis - Pipeline Review, H2 2015’, provides an overview of the Psoriasis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.
RnRMarketResearch.com adds “Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H2 2014” to its store. This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with comparative analysis at various stages.
Download Sample Brochure@ http://tinyurl.com/zk89e5j Marketintelreports, ‘Duchenne Muscular Dystrophy - Pipeline Review, H2 2015’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.
Download Sample Brochure@ http://tinyurl.com/zk89e5j Marketintelreports, ‘Duchenne Muscular Dystrophy - Pipeline Review, H2 2015’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects.
Download Sample Brochure @ http://tinyurl.com/glhfd29 Marketintelreports, ‘Staphylococcus Aureus Infections - Pipeline Review, H2 2015’, provides an overview of the Staphylococcus Aureus Infections’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.
Download Sample Brochure @ http://tinyurl.com/h8q2pqr Marketintelreports, ‘Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2015’, provides an overview of the Kidney Cancer (Renal Cell Cancer)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer) and special features on late-stage and discontinued projects.
This report is an essential source of information and analysis on the global Vitiligo Therapeutics market. The report identifies the key trends shaping and driving the global Vitiligo Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1uksROs
Big Market Research, Global Pharma Point Macular Edema and Macular Degeneration Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). The ME market has been dominated by anti-VEGF drugs Lucentis and Avastin for many years, however, rival drug Eylea has recently gained approval for ME indications across the 7MM. How will this impact the positions that Lucentis and Avastin hold in this market.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Cystic Fibrosis Transmembrane conductance Regulators (CFTR) modulators are the first type of CF therapy to treat the root cause of the disease rather than the symptoms, and as a result, they offer patients improved relief and quality of life. Kalydeco (ivacaftor), which has been marketed since 2012, was the first CFTR modulator to reach the market, and despite only treating a small proportion of the CF population, it had a large impact on the value of the market. Complete report is available @ http://www.rnrmarketresearch.com/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-market-report.html .
Reports and Intelligence adds a report on “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”. The report is designed with an aim to provide the market investors with full-fledged knowledge of the market trends and factors influencing the growth of the market. Detailed report at: http://www.reportsandintelligence.com/non-hodgkin-lymphoma-therapeutics-in-major-developed-to-2020-new-entrants-and-promising-pipeline-widen-targeted-and-immunotherapeutic-treatment-options-market
The industry analysis specialist, has released its new report, Chronic Urticaria Or Hives Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Chronic Urticaria Or Hives Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Urticaria Or Hives Therapeutics market. For more information : http://bit.ly/1ymlw1C
The report is an essential source of information and analysis on the global Supraventricular Tachycardia (SVT) Therapeutics market. The report identifies the key trends shaping and driving the global Supraventricular Tachycardia (SVT) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1xcXPKC
The report identifies the key trends shaping and driving the global Athletes Foot Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1vV3RPK
"Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. Browse full report @ http://bit.ly/1BbQiQv
GBI Research, a leading business intelligence provider, has released its latest research report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth”. The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. Detailed report at: http://www.reportsandintelligence.com/cystic-fibrosis-therapeutics-in-major-developed-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-growth-market
A leading business intelligence provider, has released its latest research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth".
The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Unstable Angina Therapeutics sector. For more information : http://bit.ly/1y2gJRa
A leading business intelligence provider, has released its latest research report, "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany".
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. Detailed report at: http://www.reportsandintelligence.com/antihypertensive-therapeutics-in-major-developed-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries-market